Patent · US Active

Azepane inhibitors of menin-MLL interaction

US11530226B2 · kind B2 · utility

0Cited by

0References

8Claims

0Family size

Assignee

Janssen Pharmaceuticals, Inc. · BE

Inventors

Patrick René Angibaud · Louviers, FR
Vineet Pande · Vosselaar, BE
Barbara Herkert · Flonheim, DE
Daniel Jason Krosky · Blue Bell, US
Olivier Alexis Georges Querolle · Évreux, FR
Aaron Nathaniel Patrick · Doylestown, US
Isabelle Noëlle Constance Pilatte · Louviers, FR

Key dates

Filing date	Jul 17, 2020
Grant date	Dec 20, 2022
Priority date	—
Expiry date	Jul 17, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.